Najmeh Moradi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9178969/publications.pdf

Version: 2024-02-01

27	232	8	14
papers	citations	h-index	g-index
33	33	33	301 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	The effect of risk communication on preventive and protective Behaviours during the COVID-19 outbreak: mediating role of risk perception. BMC Public Health, 2021, 21, 54.	2.9	68
2	Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit. Archives of Iranian Medicine, 2021, 24, 139-143.	0.6	21
3	High prevalence of occult hepatitis C virus infection in injection drug users with HIV infection. Archives of Virology, 2019, 164, 2493-2504.	2.1	15
4	Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran. Applied Health Economics and Health Policy, 2018, 16, 837-846.	2.1	13
5	Willingness to pay for one quality-adjusted life year in Iran. Cost Effectiveness and Resource Allocation, 2019, 17, 4.	1.5	13
6	Policies to improve access to pharmaceutical products in shortage: the experience of Iran food and drug administration. DARU, Journal of Pharmaceutical Sciences, 2019, 27, 169-177.	2.0	12
7	The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method. PharmacoEconomics - Open, 2019, 3, 311-319.	1.8	9
8	Men's willingness to pay for prostate cancer screening: a systematic review. Systematic Reviews, 2020, 9, 290.	5.3	9
9	Monetary Value of Quality-Adjusted Life Years (QALY) among Patients with Cardiovascular Disease: a Willingness to Pay Study (WTP). Iranian Journal of Pharmaceutical Research, 2017, 16, 823-833.	0.5	9
10	Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations. Hereditary Cancer in Clinical Practice, 2021, 19, 35.	1.5	8
11	Molecular diagnosis of occult hepatitis C virus infection in Iranian injection drug users. Archives of Virology, 2019, 164, 349-357.	2.1	7
12	Willingness to Pay for One Quality Adjusted Life Years In Patients With Diabetes. Value in Health, 2015, 18, A616-A617.	0.3	6
13	Affordability Assessment from a Static to Dynamic Concept: A Scenario-Based Assessment of Cardiovascular Medicines. International Journal of Environmental Research and Public Health, 2020, 17, 1710.	2.6	6
14	An application of analytic network process model in supporting decision making to address pharmaceutical shortage. BMC Health Services Research, 2020, 20, 626.	2.2	6
15	An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran. Cost Effectiveness and Resource Allocation, 2020, 18, 47.	1.5	4
16	Barriers and Drivers of Public Preventive Behavioral Responses to COVID-19 Outbreak: Evidence from Iran. Health Scope, 2021, 10, .	0.6	4
17	Private Demand for Covid-19 Vaccine: A Contingent Assessment from a Low-and Middle-income Country Iranian Journal of Pharmaceutical Research, 2021, 20, 223-234.	0.5	4
18	Evaluating the preventive and curative effects of <i>Toxocara canis</i> larva in Freund's complete adjuvantâ€induced arthritis. Parasite Immunology, 2020, 42, e12760.	1.5	3

#	Article	IF	CITATIONS
19	Affordability of Medication Therapy in Diabetic Patients: A Scenario-Based Assessment in Iran's Health System Context. International Journal of Health Policy and Management, 2020, , .	0.9	3
20	Willingness to Pay for Complementary Health Care Insurance in Iran. Iranian Journal of Public Health, 2017, 46, 1247-1255.	0.5	3
21	Cost-Effectiveness of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy Versus Systematic Transrectal Ultrasound-Guided Biopsy for Prostate Cancer Diagnosis: A Systematic Review. Value in Health Regional Issues, 2022, 30, 31-38.	1.2	3
22	Willingness to pay for and acceptance of cervical cancer prevention methods: A systematic review and meta-analysis. Medical Journal of the Islamic Republic of Iran, 2021, 35, 81.	0.9	2
23	Public Views on Priority Groups for COVID-19 Vaccination: A Survey from Iran. Shiraz E Medical Journal, 2021, 22, .	0.3	2
24	Health State Utilities for Patient's Current Health from Bipolar Type I Disorder. Journal of Mental Health Policy and Economics, 2018, 21, 3-10.	0.6	2
25	How to Maintain Pharmaceutical Access in Crisis: The Iran FDA Experience. Value in Health, 2017, 20, A665-A666.	0.3	0
26	Managing Pharmaceutical Expenditures: Estimating the Effect of Internal Reference Pricing for Three Pharmacological Categories. Avicenna Journal of Pharmaceutical Research, 2020, 1, 76-81.	0.0	0
27	COVID-19: The Challenge of Disadvantaged Groups and their Access to Care. Archives of Iranian Medicine, 2020, 23, 647-648.	0.6	O